Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kamada ( (IL:KMDA) ) just unveiled an update.
Kamada Ltd. reported strong financial results for the second quarter and first half of 2025, with an 11% year-over-year increase in total revenues to $88.8 million and a 35% rise in adjusted EBITDA to $22.5 million. The company raised its full-year profitability guidance and announced FDA approval for its plasma collection center in Houston, Texas, which is expected to significantly contribute to its revenue. Kamada continues to focus on business development opportunities and advancing its clinical trials to support long-term growth.
The most recent analyst rating on (IL:KMDA) stock is a Hold with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in the development and commercialization of plasma-derived protein therapeutics. It focuses on rare and serious conditions, with a strong presence in the specialty plasma-derived field.
Average Trading Volume: 42,249
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.45B
For detailed information about KMDA stock, go to TipRanks’ Stock Analysis page.